NovaBay Pharmaceuticals Inc (NBY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has a cash flow conversion efficiency ratio of 0.100x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.27 Million) by net assets ($-22.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NBY equity to assets ratio to measure how much of total assets are equity-financed.
NovaBay Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NovaBay Pharmaceuticals Inc (NBY) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
NovaBay Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ihuman Inc
NYSE:IH
|
0.193x |
|
Snail, Inc. Class A Common Stock
NASDAQ:SNAL
|
-0.518x |
|
Champ Resto Indonesia PT
JK:ENAK
|
0.207x |
|
Freemelt Holding AB
ST:FREEM
|
-0.037x |
|
Fridenson
TA:FRDN
|
-0.054x |
|
Avante Logixx Inc
V:XX
|
0.072x |
|
Industrial Investment Trust Limited
NSE:IITL
|
0.148x |
|
Enjoei S.A
SA:ENJU3
|
0.112x |
Annual Cash Flow Conversion Efficiency for NovaBay Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of NovaBay Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see NBY market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-22.83 Million | $-8.43 Million | 0.369x | -99.08% |
| 2024-12-31 | $-129.00K | $-5.18 Million | 40.178x | +3224.87% |
| 2023-12-31 | $3.31 Million | $-4.26 Million | -1.286x | -103.94% |
| 2022-12-31 | $10.55 Million | $-6.65 Million | -0.630x | +30.24% |
| 2021-12-31 | $10.17 Million | $-9.19 Million | -0.904x | -135.80% |
| 2020-12-31 | $12.32 Million | $-4.72 Million | -0.383x | +95.30% |
| 2019-12-31 | $973.00K | $-7.93 Million | -8.149x | -625.04% |
| 2018-12-31 | $4.95 Million | $-5.57 Million | -1.124x | +53.50% |
| 2017-12-31 | $2.59 Million | $-6.27 Million | -2.417x | -41.44% |
| 2016-12-31 | $7.10 Million | $-12.13 Million | -1.709x | -146.94% |
| 2015-12-31 | $-5.10 Million | $-18.56 Million | 3.640x | +144.69% |
| 2014-12-31 | $1.85 Million | $-15.05 Million | -8.147x | -434.94% |
| 2013-12-31 | $8.52 Million | $-12.97 Million | -1.523x | -227.75% |
| 2012-12-31 | $14.05 Million | $-6.53 Million | -0.465x | -38.19% |
| 2011-12-31 | $9.34 Million | $-3.14 Million | -0.336x | -273.93% |
| 2010-12-31 | $10.49 Million | $2.03 Million | 0.193x | +256.55% |
| 2009-12-31 | $13.35 Million | $-1.65 Million | -0.123x | +90.88% |
| 2008-12-31 | $7.34 Million | $-9.94 Million | -1.354x | -209.09% |
| 2007-12-31 | $14.32 Million | $-6.27 Million | -0.438x | -116.74% |
| 2006-12-31 | $1.81 Million | $4.74 Million | 2.617x | +363.45% |
| 2005-12-31 | $3.25 Million | $-3.23 Million | -0.993x | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more